45 aminoglycosides
Upcoming SlideShare
Loading in...5
×
 

45 aminoglycosides

on

  • 2,617 views

 

Statistics

Views

Total Views
2,617
Views on SlideShare
2,615
Embed Views
2

Actions

Likes
1
Downloads
147
Comments
0

2 Embeds 2

http://englishtest0.blogspot.com 1
http://englishtest0.blogspot.in 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

45 aminoglycosides 45 aminoglycosides Presentation Transcript

  • AMINOGLYCOSIDES Anita Q. Sangalang, MD, FPOGS FACULTY OF PHARMACY UNIVERSITY OF SANTO TOMAS
  • AMINOGLYCOSIDES MODES OF ANTIBACTERIAL ACTION  Treatment of microbial infection with antibiotics • Multiple daily dosing • Maintain serum concentration level above the minimum inhibitory concentration (MIC)
  • AMINOGLYCOSIDESMODES OF ANTIBACTERIAL ACTIONCONCENTRATION DEPENDENT Some drugs and aminoglycosides • As the plasma level is increased above the MIC, the drug kills an increasing proportion of bacteria at a more rapid rate
  • AMINOGLYCOSIDESMODES OF ANTIBACTERIAL ACTIONTIME DEPENDENT Any antibiotics, including penicillin and cephalosporins • Directly related to time above MIC • Independent of concentration once the MIC is reached
  • AMINOGLYCOSIDESMODES OF ANTIBACTERIAL ACTIONPOSTANTIBIOTIC EFFECT Aminoglycosides’ killing action continues when the plasma levels have declined below measurable levels
  • AMINOGLYCOSIDESMODES OF ANTIBACTERIAL ACTIONPOSTANTIBIOTIC EFFECT Greater efficacy when administered as a single large dose than when given as multiple smaller doses
  • AMINOGLYCOSIDESMODES OF ANTIBACTERIAL ACTION Toxicity (in contrast to antibacterial activity) depends on a critical plasma concentration and on that time such a level is exceeded Time above such threshold is shorter with single large dose Basis for once-daily dosing protocols
  • AMINOGLYCOSIDES PHARMACOKINETICS  Structurally related amino sugars attached by glycosidic linkages  Polar compounds  Not absorbed orally
  • AMINOGLYCOSIDES PHARMACOKINETICS  Given intramuscularly or intravenously for systemic effects  Limited tissue penetration  Do not readily cross the blood-brain barrier
  • AMINOGLYCOSIDES PHARMACOKINETICS  Major mode of excretion • Glomerular filtration  Plasma levels are affected by changes in renal function
  • AMINOGLYCOSIDESPHARMACOKINETICS Excretion is directly proportional to creatinine clearance With normal renal function, elimination half-life is 2-3 h
  • AMINOGLYCOSIDESPHARMACOKINETICS Dosage adjustment must be made in renal insufficiency to avoid toxic accumulation Monitoring plasma levels is needed for safe and effective dosage selection and adjustment
  • AMINOGLYCOSIDESPHARMACOKINETICS For traditional dosing regimens • 2 or 3 times daily • Peak serum levels • Measured at 30-60 minutes after administration • Trough serum levels • Measured just before the next dose
  • AMINOGLYCOSIDESMECHANISM OF ACTION Bactericidal (irreversible) inhibitors of protein synthesis Penetration of bacterial cell wall is partly dependent on O2-dependent active transport
  • AMINOGLYCOSIDES MECHANISM OF ACTION  Minimal activity against strict anaerobes  Transport is enhanced by cell wall synthesis inhibitors • Antimicrobial synergism
  • AMINOGLYCOSIDESMECHANISM OF ACTION Bind to 30S ribosomal unit Interfere with protein synthesis 1. Block formation of initiation complex 2. Cause misreading of the code on the mRNA template 3. Inhibit translocation
  • AMINOGLYCOSIDES MECHANISMS OF RESISTANCE  Resistant due to failure to penetrate into the cell • Streptococci, including S. pneumoniae • Enterococci
  • AMINOGLYCOSIDESMECHANISMS OF RESISTANCE Plasmid-mediated formation of inactivating enzymes • Primary mechanism of resistance • Varying susceptibility to the enzyme
  • AMINOGLYCOSIDESMECHANISMS OF RESISTANCE Plasmid-mediated formation of inactivating enzymes • Group transferases • Catalyze the acetylation of amine functions • Transfer of phosphoryl or adenyl groups to the O2 atoms of hydroxyl groups on the aminoglycoside
  • AMINOGLYCOSIDESMECHANISMS OF RESISTANCE Plasmid-mediated formation of inactivating enzymes • Transferases produced by enterococci can inactivate • Amikacin • Gentamicin • Tobramycin • Not streptomycin
  • AMINOGLYCOSIDESMECHANISMS OF RESISTANCE Plasmid-mediated formation of inactivating enzymes • Netilmicin is less susceptible and is active against more strains of organisms
  • AMINOGLYCOSIDESCLINICAL USESGENTAMICIN, TOBRAMYCIN, and AMIKACIN Serious infections caused by aerobic gram (-) bacteria • E. coli Enterobacter • Klebsiella Proteus • Providencia Pseudomonas • Serratia
  • AMINOGLYCOSIDESCLINICAL USESGENTAMICIN, TOBRAMYCIN, and AMIKACIN Used for the following but is not the drug of choice • H. influenzae • M. catarrhalis • Shigella species
  • AMINOGLYCOSIDES CLINICAL USES ANTIBACTERIAL SYNERGY  Not effective for gram (+) cocci when used alone  Combination of aminoglycoside and cell wall synthesis inhibitors
  • AMINOGLYCOSIDESCLINICAL USESANTIBACTERIAL SYNERGY Combined with penicillin in the treatment • Pseudomonal • Listerial • Enterococcal infections
  • AMINOGLYCOSIDESCLINICAL USESSTREPTOMYCIN Tuberculosis Plague Tularemia Multi-drug-resistant (MDR) strains of M. tb resistant to streptomycin maybe susceptible to amikacin
  • AMINOGLYCOSIDES CLINICAL USES NEOMYCIN  Used topically  Locally • In the GIT • Eliminate bacterial flora
  • AMINOGLYCOSIDES CLINICAL USES NETILMICIN  Reserved for serious infections resistant to other aminoglycosides
  • AMINOGLYCOSIDESCLINICAL USESSPECTINOMYCIN Aminocylitol related to aminoglycosides Back-up drug Intramuscular as single dose for gonorrhea
  • AMINOGLYCOSIDES TOXICITY B. OTOTOXICITY  Auditory or vestibular damage (or both) maybe irreversible • Auditory impairment • Amikacin and kanamycin • Vestibular dysfunction • Gentamicin and tobramycin
  • AMINOGLYCOSIDESTOXICITYB. OTOTOXICITY Risk is proportionate to the plasma levels • High if dosage is not modified in renal dysfunction Increased with the use of loop diuretics Contraindicated in pregnancy
  • AMINOGLYCOSIDES TOXICITY B. NEPHROTOXICITY  Acute tubular necrosis  Reversible  Most nephrotoxic • Gentamicin and tobramycin
  • AMINOGLYCOSIDES TOXICITY B. NEPHROTOXICITY  More common in elderly patients  Patients concurrently receiving • Amphotericin B • Cephalosporins • Vancomycin
  • AMINOGLYCOSIDESTOXICITYB. NEUROMUSCULAR BLOCKADE Rare Curare-like block may occur at high doses • Respiratory paralysis Reversible
  • AMINOGLYCOSIDES TOXICITY B. NEUROMUSCULAR BLOCKADE  Treatment • Calcium • Neostigmine • Ventilatory support
  • AMINOGLYCOSIDES TOXICITY B. SKIN REACTIONS  Neomycin • Allergic skin reactions like contact dermatitis